Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy

TL;DR

CAR-T cell therapy is a powerful immunotherapy that has shown success in blood cancers and autoimmune diseases, but faces challenges in treating solid tumors.

Contribution

The paper reviews recent advances in CAR-T cell engineering and strategies to improve their effectiveness in solid tumors and other diseases.

Findings

CAR-T cells targeting CD19 have achieved high remission rates in hematologic malignancies.

CAR-T therapy shows promise in autoimmune diseases like systemic lupus erythematosus.

Challenges in solid tumors include antigen heterogeneity and an immunosuppressive tumor microenvironment.

Abstract

Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative form of immunotherapy, enabling the precise engineering of T cells to recognize and eliminate pathogenic cells. In hematologic malignancies, CAR-T cells targeting CD19 or B cell maturation antigens have achieved remarkable remission rates and durable responses in patients with otherwise refractory disease. Despite these successes, extending CAR-T cell therapy to solid tumors remains challenging due to antigen heterogeneity, poor T cell infiltration, and the immunosuppressive tumor microenvironment (TME). Beyond oncology, CAR-T cell therapy has also shown promise in autoimmune diseases, where early clinical studies suggest that B cell-directed CAR-T cells can induce sustained remission in conditions such as systemic lupus erythematosus. This review highlights advances in CAR-T cell engineering, including DNA- and mRNA-based platforms for ex vivo and in vivo programming, and discusses emerging strategies to enhance CAR-T cell trafficking, persistence, and resistance to TME.

Figures